Introduction {#s1}
============

Obstructive sleep apnea syndrome (OSAS) is a respiratory disorder characterized by upper airway obstruction during sleep, breathing pauses with oxygen desaturation, and arousal from sleep. OSAS is the third most prevalent respiratory disease after asthma and chronic obstructive pulmonary disease [@pone.0095856-Young1]. It has been estimated that about 2--4% of middle-aged people are affected by OSAS. OSAS is recognized as a chronic, complex disease related to metabolic syndrome, cardiovascular disease, neurocognitive and mood disorders [@pone.0095856-Bradley1]. With the rise in overweight and obesity, the prevalence of OSAS should increase, representing a serious public-health problem with substantial social and economic costs [@pone.0095856-Mannarino1].

Although the pathogenetic mechanism of OSAS remains unclear, many factors have been incriminated. A combination of genetic makeup and environmental factors could contribute to the development of OSAS. The high concordance of first-degree relatives with OSAS, family clustering, and ethnic differences show that genetic factors may play an important role in the pathogenesis of OSAS [@pone.0095856-Schwab1]. It has been reported that genetic factors could account for about 40% of the variance in the apnea-hypopnea index (AHI) of OSAS patients [@pone.0095856-Redline1]. It is currently thought that multiple gene interactions in a suitable environment may lead to OSAS [@pone.0095856-Casale1].

Evaluation of the genetic contribution to the occurrence of OSAS is of interest [@pone.0095856-Kent1]. Several polymorphisms have been suggested to play a role and a number of family and SNP studies have been performed. Serotonin (5-hydroxytryptamine; 5-HT) regulates a variety of physiological functions through 5-HT receptors (5-HT2A, 5-HT2B, 5-HT2C). These play a critical role in the patency of the upper airway and the prevention of glossocoma. A functional gene polymorphism of 5-HT2A has been identified to alter gene transcription, thus influencing the expression level of the receptor [@pone.0095856-Huang1]. Polymorphisms in the 5-HT2A gene, characterized by reduction of receptor number and serotonin concentration in postsynaptic neurons, were associated with the development of OSAS [@pone.0095856-Stang1], [@pone.0095856-Liang1]. 5-HT reuptake is mediated by the serotonin transporter (5-HTT) [@pone.0095856-Stroup1], [@pone.0095856-Higgins1]. Polymorphisms of this gene could lead to alterations in 5-HT concentrations. Two such polymorphisms (variable number tandem repeat (VNTR) and 5-HTTLPR) have been described [@pone.0095856-Biros1], [@pone.0095856-Yin1]. Uptake of serotonin in cells with the "L/L" 5-HTTLPR genotype was more than that in cells carrying the "S/L" or "S/S" genotypes. The S allele was responsible for low uptake activity. Leptin is an adipocyte-derived hormone which plays an important role in metabolic control. The potential associations of leptin and LEPR gene polymorphisms with OSAS have been assessed in different populations [@pone.0095856-Sakai1]. Although the relationship between 5-HT2A, 5-HTT, LEPR and OSAS has been evaluated, the results were not consistent. To date, no large-scale Genome-Wide Association study (GWAS) has been performed. We performed a meta-analysis to better evaluate the association between reported polymorphisms and OSAS risk.

Methods {#s2}
=======

Search Strategy {#s2a}
---------------

We searched PubMed and EMBASE in all languages for relevant studies. The final date for inclusion was March 10, 2013. Comprehensive search themes included Medical Subject Headings (MeSH) terms and keywords: "sleep apnea"; "obstructive sleep apnea Syndrome"; "sleep apnea/hypopnea syndrome" and "serotonin 2A receptor(5-HT2A)"; "serotonin transporter protein(5-HTT)"; "leptin receptor (LEPR)"; "polymorphism"; "variant"; and "genotype".

Study selection {#s2b}
---------------

Inclusion criteria for this study were: (1) OSAS patients must be clearly diagnosed; (2) the study must be a case-control study; (3) the study should report enough genotyping information to extract and estimate odds ratios (ORs) with a 95% confidence interval (CI). Studies were excluded if: (1) the diagnosis was unclear; (2) the study did not contain sufficient data for extraction; (3) the study design was based on case, family or sibling pairs; or (4) no control group was included in the study. When overlapping reports occurred, the study with largest number of patients was selected.

Data extraction {#s2c}
---------------

All included studies were retrieved and the required information was extracted separately, in duplicate, by two authors (BDQ and SZ). Any discrepancies were resolved by discussion and agreement. The characteristics collected from each study were: author, year of publication, country, age, AHI, sample size, diagnosis criteria, genotype, allele frequency, and specific technique of analysis. If the allele frequency was not given, it was calculated from the corresponding genotype distributions. The OR with its 95%CI was extracted or calculated for each study.

Assessment of study quality {#s2d}
---------------------------

There is no standard quality criteria for single nucleotide polymorphism (SNP) studies, so we employed a modified Newcastle-Ottawa scale (NOS) score system to assess the quality of these non-randomized studies [@pone.0095856-Bayazit1]. A total of eight items are included in the NOS. These are divided into three categories describing selection, comparability and exposure. A maximum of two stars was given for each of these items. A study awarded 0--3 stars was classified as a low quality study, while 4--6 stars and 7--9 stars were moderate and high quality studies, respectively [@pone.0095856-deCarvalho1].

Statistical analysis {#s2e}
--------------------

We performed a systematic review and meta-analysis following a predetermined protocol in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines [@pone.0095856-Zhu1]. A meta-analysis was performed of polymorphisms of the 5-HT2A, 5-HTT, and LEPR genes, to examine their association with OSAS using additive, recessive and dominant models. The pooled ORs with 95%CIs were calculated in random-effects or fixed-effects models to measure the strength of the associations between these polymorphisms and OSAS risk. Heterogeneity of effects across studies was evaluated using the means of χ^2^-based Q test and I^2^ test. P\<0.10 was considered to be representative of significant heterogeneity with the Q test. The I^2^ statistic represented quantification of heterogeneity ranging from 0% to 100%. Hundred percent represented a high degree of heterogeneity and 50%-\<100% represented substantial heterogeneity [@pone.0095856-Chen1]. If there was significant heterogeneity (P\<0.10 for Q test; I^2^\>50% for I^2^ test), a random-effects model was used to pool the data. Otherwise, a fixed-effects model was used. A funnel plot was employed to visually assess potential publication bias in meta-analyses including more than five studies. The Egger\'s regression asymmetry test and Begg\'s rank correlation test were used to statistically examine publication bias. A sensitivity analysis was performed to assess the impact of each individual study upon the overall ORs, using the one-study removal approach [@pone.0095856-Ylmaz1]. Hardy-Weinberg Equilibrium was assessed using χ2 tests for the polymorphism investigated in each study. All analyses were conducted using STATA 11.0 (StataCorp, College Station TX, USA). P\<0.05 was considered statistically significant.

Result {#s3}
======

Studies selection {#s3a}
-----------------

Two hundred fifty-six non-overlapping articles were identified in the initial published work search. Two hundred eighteen articles were excluded based on screening of abstracts or titles. Thirty-eight full-text articles were retrieved and assessed for eligibility. Twenty-six of these articles were excluded ([**Figure 1**](#pone-0095856-g001){ref-type="fig"}), leaving twelve eligible studies in this present study.

![The flowchart showing articles identification, inclusion and exclusion.](pone.0095856.g001){#pone-0095856-g001}

Characteristics of included studies {#s3b}
-----------------------------------

Nine of the twelve studies included were in English and three in were Chinese. One thousand twenty OSAS patients and one thousand eighty-three control subjects were reported [@pone.0095856-Stang1], [@pone.0095856-Liang1], [@pone.0095856-Biros1]--[@pone.0095856-Sakai1], [@pone.0095856-Yue1]--[@pone.0095856-Riha1]. Six of the twelve studies were conducted to clarify the association between 5-HT2A polymorphisms and OSAS. These studies included 728 OSAS patients and 566 controls subjects. Four studies evaluated 5-HTT polymorphisms and included 521 OSAS patients and 755 control subjects. Three studies evaluated the LEPR polymorphism and included 292 OSAS patients and 167 control subjects. ORs with 95% CIs were extracted from each study. A database was established for the information or characteristics extracted from these studies ([**Table 1**](#pone-0095856-t001){ref-type="table"} and [**Table 2**](#pone-0095856-t002){ref-type="table"}). The 12 reports included patients of American (n = 1), Asian (n = 8), and European (n = 3) ethnicity. The number of patients in each report ranged from 100 to 592. The diagnosis of OSAS was based on symptoms and polysomnography (PSG). Hardy-Weinberg equilibrium testing showed deviation from HWE in some of the studies (**[Table S1](#pone.0095856.s001){ref-type="supplementary-material"}**).

10.1371/journal.pone.0095856.t001

###### Characteristic of the included studies about the association between 5-HT2A polymorphism and OSAS risk.

![](pone.0095856.t001){#pone-0095856-t001-1}

                     Author         Year   Country   Age(Case/Control)   AHI(Case/Control)   Case/Control        Diagnosis        Genotype Method   Genotype Frequency        
  ----------- -------------------- ------ --------- ------------------- ------------------- -------------- --------------------- ----------------- -------------------- ----- ----
  102C/T           Yin, et al       2011    China     41.4±9.2**~⊢~**    42.3±22.1**~⊢~**      210/105      PSG AHI ≥5 events/h         PCR                 TT           52    30
                                                     40.6±10.4**~⊤~**     2.3±1.6**~⊤~**                                                                    CT           107   51
                                                                                                                                                            CC           51    24
                  Sakai, et al      2005    Japan        48.3±10.1           46.1±25.8         177/100      PSG AHI ≥5 events/h         PCR                 TT           47    25
                                                        38\. ±11.1              NS                                                                          CT           90    46
                                                                                                                                                            CC           40    29
                 Bayazit, et al     2006   Turkey           NS                  NS              55/102              PSG                 PCR                 TT           17    28
                                                            NS                  NS                            Muller Maneuver                               CT           21    54
                                                                                                               Laryngoscopy                                 CC           17    20
               De Carvalho, et al   2013   brazil        50.6±11.1           32.6±25.7         100/100      PSG AHI ≥5 events/h         PCR                 TT           23    20
                                                         44.6±12.0            1.9±1.5                                                                       CT           66    69
                                                                                                                                                            CC           11    11
                   Zhu, et al       2007    China        44.2±2.0               NS              65/54               PSG                 PCR                 TT           18    15
                                                         43.0±2.1               NS                                                                          CT           30    28
                                                                                                                                                            CC           17    11
                  Chen, et al       2013    China        43.8±3.0            42.6±14.8         121/105      PSG AHI ≥5 events/h         PCR                 TT           34    29
                                                         43.0±2.7             3.7±1.3                        AHI ≥15 events/h                               CT           56    54
                                                                                                                                                            CC           31    22
  -1438 G/A        Yin, et al       2011    China        41.4±9.2            42.3±22.1         210/105      PSG AHI ≥5 events/h         PCR                 AA           85    17
                                                         40.6±10.4            2.3±1.6                                                                       AG           82    67
                                                                                                                                                            GG           43    21
                 Bayazit, et al     2006   Turkey           NS                  NS              55/102              PSG                 PCR                 AA           24    25
                                                            NS                  NS                            Muller Maneuver                               AG           29    50
                                                                                                               Laryngoscopy                                 GG           12    27
                 Piatto, et al      2011   brazil        50.6±11.1           32.6±25.7         100/100      PSG AHI ≥5 events/h         PCR                 AA           35    19
                                                         44.6±12.0            1.9±1.5                                                                       AG           61    71
                                                                                                                                                            GG            4    10
                   Zhu, et al       2007    China        44.2±2.0               NS              65/54               PSG                 PCR                 AA           41    15
                                                         43.0±2.1               NS                                                                          AG           15    14
                                                                                                                                                            GG            9    25
                  Chen, et al       2013    China        43.8±3.0            42.6±14.8         121/105      PSG AHI ≥5 events/h         PCR                 AA           74    28
                                                         43.0±2.7            3.72±1.28                                                                      AG           30    28
                                                                                                                                                            GG           17    49

NS: None Stated.

⊢: Indicated age of OSAS patients group in these studies.

**⊤**: Indicated age of Control group in these studies.

10.1371/journal.pone.0095856.t002

###### Characteristic of the included studies about the associations between 5-HTT, LEPR polymorphisms and OSAS risk.

![](pone.0095856.t002){#pone-0095856-t002-2}

              Author      Year   Country   Age(Case/Control)   AHI(Case/Control)   Case/Control        Diagnosis         Genotype Method   Genotype Frequency        
  ------- -------------- ------ --------- ------------------- ------------------- -------------- ---------------------- ----------------- -------------------- ----- -----
  5-HTT    Chen, et al    2013    China       43.8±3.0~⊢~        42.6±14.8~⊢~        121/105      PSG AHI ≥5 events/h         PCR)                 SS           59    55
  LPR                                       43.0±2.7**~⊤~**     3.7±1.3**~⊤~**                      AHI ≥15 events/h                               SL           35    34
                                                                                                                                                   LL           27    16
           Ylmaz, et al   2005   Turkey           NA                  NS              42/162              PSG                  PCR                 SS            6    60
                                                  NA                  NS                                                                           SL           16    71
                                                                                                                                                   LL            4    35
            Yue, et al    2008    China        45.2±11.8           53.9±16.4         254/338      PSG AHI ≥5 events/h          PCR                 SS           114   173
                                               43.2±12.7              NS                                                                           SL           106   131
                                                                                                                                                   LL           34    34
            Yue, et al    2005    China        42.3±10.1              NS             104/150      PSG AHI ≥10 events/h         PCR                 SS           51    78
                                                  NA                  NS                                                                           SL           33    54
                                                                                                                                                   LL           20    18
  5-HTT    Chen, et al    2013    China        43.8±3.0            42.6±14.8         121/105      PSG AHI ≥5 events/h          PCR               10/10           8     1
  VNTR                                         43.0±2.7             3.7±1.3                         AHI ≥15 events/h                             10/12          24    10
                                                                                                                                                 12/12          89    94
           Ylmaz, et al   2005   Turkey           NA                  NS              42/162              PSG                  PCR               10/10           3    14
                                                  NA                  NS                                                                         10/12          13    61
                                                                                                                                                 12/12           9    93
            Yue, et al    2008    China        45.2±11.8           53.9±16.4         254/338      PSG AHI ≥5 events/h          PCR               10/10           6     3
                                               43.2±12.7              NS                                                                         10/12          46    41
                                                                                                                                                 12/12          202   294
            Yue, et al    2005    China        42.3±10.1              NS             104/150      PSG AHI ≥10 events/h         PCR               10/10           3     1
                                                  NA                  NS                                                                         10/12          20    14
                                                                                                                                                 12/12          81    135
  LEPR     Popko, et al   2007   Poland         21--77                \>5             102/77      PSG AHI ≥5 events/h       PCR assay           Gln/Gln         18    26
                                                18--65                \<5                                                                       Gln/Arg         61    40
                                                                                                                                                Arg/Arg         23    11
             Hanaoka,     2008    Japan        50.3±2.0            49.1±3.9           130/50      PSG AHI ≥10 events/h         PCR              Gln/Gln         63    21
              et al                            50.0±4.4             2.1±0.5                                                                     Gln/Arg         57    28
                                                                                                                                                Arg/Arg          5     1
              Huang,      2003    China        43.4±0.8               NS              60/40               PSG               PCR-RFLP            Gln/Gln         79    64
              et al                            43,9±1.2               NS                                                                        Gln/Arg         22    23
                                                                                                                                                Arg/Arg          2     1

NS: None Stated.

⊢: Indicated age of OSAS patients group in these studies.

**⊤**: Indicated age of Control group in these studies.

5-HT2A 102 C/T and OSAS {#s3c}
-----------------------

Six studies evaluated the association between 5-HT2A 102C/T and OSAS. The pooled data revealed no significant association between 5-HT2A 102C/T polymorphism and OSAS risk, using any model ([**Table 3**](#pone-0095856-t003){ref-type="table"}). The frequency of the minor "C" allele was not significantly different in OSAS patients and controls (OR: 0.97, 95%CI 0.83--1.14), suggesting that the polymorphism was not linked to OSAS development. There was no significant heterogeneity in this meta-analysis. Subgroup meta-analysis stratified by ethnicity found no significant association with Caucasian or Asian populations.

10.1371/journal.pone.0095856.t003

###### Meta-analysis of associations between 5-HT2A, 5-HTT, LEPR polymorphisms and OSAS in the additive, dominant and recessive Models.

![](pone.0095856.t003){#pone-0095856-t003-3}

  SNP                     Comparison          OR with 95%CI            Heterogeneity            Publication Bias          
  ----------------- ---------------------- ------------------- ------ --------------- -------- ------------------ ------- -------
  5-HT2A 102 C/T            T vs C          0.97(0.83--1.14)    2.02       0.846       0.00%           0           0.707   0.449
                           TT vs CT         1.07(0.81--1.40)    1.98       0.852       0.00%           0           0.133   0.087
                           TT vs CC         0.93(0.67--1.29)    2.07       0.839       0.00%           0           1.000   0.699
                           CC vs CT         1.13(0.84--1.50)    5.63       0.344       11.20%        0.017         0.452   0.213
                         TT+CT vs CC        0.90(0.69--1.19)    4.67       0.458       0.00%           0           1.000   0.316
                         CC+CT vs TT        0.98(0.76--1.26)    1.06       0.957       0.00%           0           0.707   0.263
  5-HT2A-1438 G/A           A vs G          2.33(1.49--3.66)    22.9         0         82.60%        0.217         0.462   0.458
                           AA vs GG         4.22(2.38--7.49)    8.49       0.075       52.90%        0.222         1.000   0.989
                           GG vs AG         0.66(0.31--1.40)    15.2       0.004       73.60%        0.524         0.806   0.296
                           AA vs AG         2.78(2.03--3.81)    2.33       0.675       0.00%           0           0.806   0.543
                         AA+AG vs GG        2.44(1.11--5.38)    20.8         0         80.70%        0.637         0.806   0.631
                         GG+AG vs AA        0.30(0.23--0.40)    3.53       0.473       0.00%           0           0.806   0.747
  5-HTTLPR                  S vs L          0.80(0.67--0.95)    0.07       0.995       0.00%           0           1.000   0.435
                           SS vs LL         0.65(0.46--0.93)    0.27       0.966       0.00%           0           1.000   0.396
                           SS vs SL         0.86(0.67--1.11)    2.76       0.430       0.00%           0           0.713   0.713
                           SL vs LL         0.77 (0.54--1.11)   3.60       0.308       16.70%        0.031         0.734   0.547
                         SS+SL vs LL        0.72(0.51--1.01)    0.22       0.977       0.00%           0           0.734   0.285
                         LL+SL vs SS        1.25(0.99--1.59)    0.98       0.805       0.00%           0           0.734   0.557
  5-HTTVNTR                10 vs 12         2.08(1.58--2.73)    3.31       0.346       9.40%                       0.089   0.278
                        10/10 vs 12/12      3.75(1.67--8.45)    1.29       0.731       0.00%           0           0.734   0.135
                        10/10 vs 10/12      1.67(0.74--3.77)    0.94       0.816       0.00%           0           0.308   0.236
                        10/12 vs 12/12      1.97(1.42--2.73)    1.35       0.718       0.00%           0           0.734   0.090
                     10/10+10/12 vs 12/12   2.14(1.57--2.91)    2.10       0.551       0.00%           0           0.734   0.187
                     10/10 vs 12/12+10/12   3.00(1.39--6.46)    1.89       0.596       0.00%           0           0.308   0.141
  LEPR                      G vs A          0.78(0.58--1.05)    3.73       0.155       46.40%        0.009         1.000   0.791
                           GG vs AA         0.39(0.17--0.88)    0.40       0.818       0.00%           0           1.000   0.042
                           GG vs AG         0.80(0.40--1.59)    5.62       0.060       64.40%        0.241         1.000   0.517
                           AA vs AG         1.46(0.71--3.04)    0.27       0.875       0.00%           0           1.000   0.703
                         AA+AG vs GG        1.32(0.65--2.67)    6.11       0.047       67.30%        0.260         1.000   0.652
                         GG+AG vs AA        0.57(0.28--1.15)    0.03       0.984       0.00%           0           1.000   0.958

5-HT2A-1438 G/A and OSAS {#s3d}
------------------------

Five studies evaluated the association between -1438 G/A polymorphism and OSAS. Dominant and recessive models were examined. Individuals carrying the "G" allele (AG+GG) had a nearly 70% reduced risk for the development of OSAS, when compared with AA homozygotes (OR: 0.30, 95%CI 0.23--0.40). Individuals with the "A" allele were more susceptible to OSAS than GG homozygotes (OR: 2.44, 95%CI 1.11--5.38). Using the additive model, a significant association was found (OR: 2.78, 95%CI 2.03--3.81 for AA *vs*. AG; OR: 4.22, 95%CI 2.38--7.50 for AA *vs*. GG). AA carriers had an increased risk of OSAS compared with individuals having an AG or GG genotype. Significant heterogeneity was observed in the recessive and additive models ([**Table 3**](#pone-0095856-t003){ref-type="table"}). The -1438 "A" allele was a candidate genetic risk factor for OSAS (OR: 2.33, 95%CI 1.49--3.66). There was significant heterogeneity across the studies with respect to the association between the "A" allele and OSAS risk (p\<0.05, I^2^ = 82.60%) ([**Figure 2**](#pone-0095856-g002){ref-type="fig"}). The association was much stronger in Asian patients than in Caucasian patients. Assessment of bias indicated that heterogeneity was mainly found across the studies based on Asian populations rather than Caucasian populations. This supports the finding that ethnicity may contribute to the high degree of heterogeneity. Due to the small number of included studies, subgroup meta-analyses and assessment of bias by other factors could not be conducted.

![Forest plot of the association between 5-HT2A-1438(A *vs*. G), 5-HTT-LPR(S *vs*. L), 5-HTT-VNTR (10 *vs*. 12), LEPR-Gln223Arg (GG *vs*. AA) and OSAS risk in the overall population (a: Meta-analysis with a random-effects model; b, c, d: Meta-analysis with a fixed-effects model).](pone.0095856.g002){#pone-0095856-g002}

5-HTT-LPR and OSAS {#s3e}
------------------

Four studies evaluated the association of 5-HTT-LPR polymorphisms with OSAS ([**Table 2**](#pone-0095856-t002){ref-type="table"}). The meta-analysis revealed that the "S" allele conferred protection against OSAS (OR: 0.80, 95%CI 0.67--0.95). Individuals with the "S" allele had a 20% lower risk of OSAS than individuals with the "L" allele ([**Figure 2**](#pone-0095856-g002){ref-type="fig"}). The additive model demonstrated a greater association of the "SS" genotype with OSAS than that of the "LL" genotype (OR: 0.65, 95%CI 0.46--0.93). There was no significant heterogeneity across the studies. The subgroup meta-analysis of ethnicity could not be performed due to the small sample size.

5-HTT-VNTR and OSAS {#s3f}
-------------------

Four studies evaluated the relationship of 5-HTT-VNTR polymorphisms with OSAS. The "10" allele was significantly associated with OSAS (OR: 2.08, 95%CI: 1.58--2.73) ([**Figure 2**](#pone-0095856-g002){ref-type="fig"}). The additive, recessive, and dominant models all showed a significant increased risk of OSAS among individuals with the "10" allele. The positive association was strongest when individuals with the "10/10" genotype" were compared with those carrying the "10/12" genotype (OR: 3.75, 95%CI: 1.7--8.45). No significant heterogeneity was found across these 4 studies.

LEPR- Gln223Arg and OSAS {#s3g}
------------------------

Three studies evaluated the relationship between LEPR- Gln223Arg and OSAS. The "GG" genotype" was associated with a low risk for OSAS, when compared with the "AA" homozygote (OR: 0.39, 95%CI 0.17--0.88) ([**Figure 2**](#pone-0095856-g002){ref-type="fig"}). A significant association was not found using recessive and dominant models. The risk of having OSAS in individuals with the "G" allele was 0.78. This was not significantly different from the "AA" allele (95%CI 0.58--1.05).

Sensitivity analysis {#s3h}
--------------------

Sensitivity analyses were performed when more than 3 studies were involved. The stability and reliability of pooled ORs were examined using the leave-one-out method. This method repeated the meta-analysis after sequential exclusion of each study. The estimated ORs were not significantly influenced by any individual study.

Publication bias {#s3i}
----------------

The funnel plots for associations between 5-HT2A 102C/T, 5-HT2A-1438G/A, and OSAS did not visually demonstrate significant publication bias (**Data not shown**). Both Begg\'s test and Egger\'s tests demonstrated no publication bias ([**Table 3**](#pone-0095856-t003){ref-type="table"}).

Study quality {#s3j}
-------------

The NOS scoring system was used to evaluate study quality. Five studies scored 8 stars, 5 studies scored 7 stars, 1 study scored 6 stars, and 1 study scored 5 stars (**[Table S2](#pone.0095856.s002){ref-type="supplementary-material"}**).

Discussion {#s4}
==========

The contribution of genetic factors to the development of OSAS is supported by the increased risk of OSAS in first-degree relatives and siblings of OSAS patients. The association between genetic polymorphisms and susceptibility to OSAS remains poorly defined due conflicting data. We conducted a systematic review of published studies investigating the role of 5-HT2A, 5-HTT, and LEPR polymorphisms in OSAS and performed a meta-analysis of these studies. 5-HT2A-1438G/A, 5-HTT-LPR, 5-HTT-VNTR, and LEPR-Gln223Arg were associated with the development of OSAS. 5-HT2A-1438 "A" and 5-HTT-VNTR "10" alleles were genetic risk factors for OSAS, while the 5-HTT-LPR "S" allele was a low risk factor for OSAS. Individuals with the "GG" LEPR-Gln223Arg genotype had a lower risk of OSAS compared to those with the "AA" genotype.

Twelve studies published between 2003 and 2013 were included in this study. Ten studies were of high quality, 2 of medium quality and no study was of low quality. These findings support the results of this study as a meaningful analysis of the available data.

The association of SNPs in the 5-HT2A, 5-HTT, and LEPR genes with OSAS has been reported with conflicting results. There is no previous meta-analysis of these reports. We found no association between 5-HT2A and 102T/C, and OSAS. The -1438G/A polymorphism of the 5-HT2A gene was associated with the development of OSAS. The -1438 "A" allele was associated with OSAS. This positive association was observed in all reports we evaluated. The "AA" genotype of 5-HT2A-1438G/A was over-represented in OSAS patients. Individuals carrying the "AA" genotype had a greater risk of OSAS than those with the "GG" genotype (OR  = 4.22). Bayazit et al. did not identify this positive association between "AA" genotype and OSAS risk. Yin found that the "AA\' genotype was over-expressed in patients with LSaO~2~ ≤75%. Both Chen et al. and Bayazit et al. found the frequency of "AA" genotype to be significantly higher in male OSAS patients. There were not enough patients in the studies we reviewed to perform these subgroup analyses.

The LPR VNTR polymorphism in the 5-HTT gene correlated with the occurrence of OSAS in some, but not all, studies. A meta-analysis was performed to better evaluate the association between LPR VNTR polymorphisms and OSAS. The "S" allele of 5-HTT-LPR and "SS" genotype was associated with a lower frequency of OSAS. The frequency of the "10" allele in the 5-HTT-VNTR was significantly higher in OSAS patients, suggesting that it was a risk factor for OSAS. These findings were consistent with those of Chen et al. and Yue et al., but not Yilmaz et al. Another observation made here was that the frequency of the "GG" genotype in exon 6 of the LEPR gene was significantly lower in OSAS patients than controls, suggesting this genotype was low risk factor.

Polymorphisms related to the development of OSAS mainly lie in the serotoninergic system, an important component of sleep and airway function during sleep. *In vitro* studies have shown that polymorphisms of the 5-HTR 2A/2C genes influence receptor expression [@pone.0095856-Liu1]. These findings give better insight into the development of OSAS and physiopathology of the disorder [@pone.0095856-Grilo1].

The GWAS has given better insight into the genetic nature of human disease, and identified several disease specific genes. The small sample size of previous studies and of this meta-analysis show the need for GWASs of large numbers of OSAS patients in order to better detect genetic associations. The GWAS approach could detect new disease genes, give clues to the pathogenesis of OSAS, and provide indicators for diagnosis, treatment, and prevention of the disease.

There were several limitations to this study. The number of included studies was relatively small, restricting the power of the study. Previous studies have shown associations between gender, SaO2, severity of disease and gene polymorphisms. The small number of patients identified in our literature review did not allow subgroup meta-analysis. The publications included in this study designed to evaluate the roles of different gene polymorphisms in OSAS. These different study designs could be a potential source of bias. Ongoing, unpublished and missing studies from the literature review could have contributed to publication bias, although the funnel plots, Egger\' test and Begg\'s test did not identify any bias. Finally, a combination of susceptibility genes and environmental factors could contribute to the development of OSAS. Our study could not evaluate gene-gene and gene--environment interactions due to the small number of patients identified. These findings need to be studied in a large cohort of OSAS patients in the future.

In conclusion, our study demonstrated that 5-HT2R, 5-HTT, and LEPR polymorphisms were significantly associated with the development of OSAS. 5-HT2A-1438 "A" and 5-HTT-VNTR "10" were independent risk factors for OSAS. The "S" allele of 5-HTT-LPR and the "GG" genotype of Gln223Arg in the LEPR gene conferred protection against OSAS. The small sample size may have affected the accuracy of our findings. GWAS is needed to better detect candidate disease genes and to expand our understanding of the genetic background of OSAS. Future research should also focus on the clinical relevance of these findings.
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